Synthesis and Biological Characterization of L-N6-(1-Iminoethyl)lysine 5-Tetrazole-amide, a Prodrug of a Selective iNOS Inhibitor

Authors:
  • STSofya Tsymbalov
    Sofya Tsymbalov
  • CDClifford R. Dorn
    Clifford R. Dorn
  • BPBarnett S. Pitzele
    Barnett S. Pitzele
  • DHDonald W. Hansen
    Donald W. Hansen
  • WMWilliam M. Moore
    William M. Moore
  • GJGina M. Jerome
    Gina M. Jerome
  • JCJane R. Connor
    Jane R. Connor
  • LBLinda F. Branson
    Linda F. Branson
  • DWDeborah L. Widomski
    Deborah L. Widomski
  • YZYan Zhang
    Yan Zhang
  • MCMark G. Currie
    Mark G. Currie

Abstract
The 5-tetrazole amide of L-N6-(1-iminoethyl)lysine (L-NIL), L-N6-(1-iminoethyl)lysine 5-tetrazole amide (1), has been prepared and evaluated. In contrast to L-NIL, 1 is a stable, nonhygroscopic, crystalline solid. Unlike L-NIL, 1 has minimal inhibitory activity in vitro on human inducible nitric oxide synthase (iNOS). However, it is rapidly converted in vivo to L-NIL and produces dose-dependent inhibition of iNOS in acute and chronic models of inflammation in the rodent with efficacy comparable to L-NIL. In addition, both 1 and L-NIL exhibit significant and comparable in vivo selectivity for the inhibition of iNOS vs endothelial NOS. Doses approximately 80-fold greater than those that inhibited inflammation do not elevate systemic blood pressure. In summary, both the physical properties and the pharmacological profile of 1 make it an ideal molecule for preclinical and clinical studies on the role of selective iNOS inhibitors in mediating inflammatory disease processes.

This publication has 11 references indexed in Scilit: